Global Glaucoma Therapeutics Market 2014-2018


Naperville, IL -- (SBWIRE) -- 04/21/2014 -- Reportstack, provider of premium market research reports announces the addition of Global Glaucoma Therapeutics Market 2014-2018 market report to its offering
About Glaucoma Therapeutics
Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is not fully known, but involves mechanical compression and/or decreased blood flow in the optic nerve. Based on whether the cause of the disease is unknown or known, glaucoma is divided into two types, open angle and closed angle glaucoma. Five main classes of medical treatment are currently used to lower intraocular pressure: prostaglandins, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, and fixed dose combinations.
Analysts forecast the Global Glaucoma Therapeutics market will grow at a CAGR of 2.53 percent over the period 2013-2018.
Covered in this Report
The Global Glaucoma Therapeutics market can be divided into five segments: Prostaglandins, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, and Fixed Dose Combinations. To calculate the market size, the report considers the revenue generated from the sales of various ophthalmic solutions used in the treatment of glaucoma. Global Glaucoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Glaucoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Key Vendors
Allergan Inc.
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Other Prominent Vendors

Acadia Pharmaceuticals Inc.
AC Immune SA
Acorn Biomedical Inc.
Advanced Cell Technology Inc.
Aerie Pharmaceuticals Inc.
Carl Zeiss Meditec Inc.
Falcon Pharmaceuticals Ltd.
Inotek Pharmaceuticals Corp.
Lexicon Pharmaceuticals Inc.
Neurotech Pharmaceuticals Inc.
NicOx SA
Otsuka Holdings Co. Ltd.
Phytopharm plc
Santen Pharmaceuticals Co. Ltd.
Senju Pharmaceutical Co. Ltd.
Valeant Pharmaceuticals International Inc.
Key Market Driver
Increasing Prevalence of Eye Disorders.
For a full, detailed list, view our report.
Key Market Challenge
Increasing Number of Patent Expirations.
For a full, detailed list, view our report.
Key Market Trend
Increase in Awareness of Glaucoma.
For a full, detailed list, view our report.
Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

Companies Mentioned

Allergan Inc. ,Merck & Co. Inc. ,Novartis AG ,Pfizer Inc.,Acadia Pharmaceuticals Inc.,AC Immune SA ,Acorn Biomedical Inc.,Advanced CellTechnology Inc.,Aerie Pharmaceuticals Inc.,Carl Zeiss Meditec Inc.,Falcon Pharmaceuticals Ltd.,Inotek Pharmaceuticals Corp.,LexiconPharmaceuticals Inc.,Neurotech Pharmaceuticals Inc. ,NicOx SA,Otsuka Holdings Co. Ltd.,Phytopharm plc,SantenPharmaceuticals Co. Ltd.,Senju Pharmaceutical Co. Ltd.,SIFI SpA,Valeant Pharmaceuticals International Inc.

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604